Literature DB >> 28274698

Effects of Short-Term Oxycodone Maintenance on Experimental Pain Responses in Physically Dependent Opioid Abusers.

Marion A Coe1, Paul A Nuzzo2, Michelle R Lofwall3, Sharon L Walsh4.   

Abstract

A common clinical problem with opioid analgesics is the loss of analgesic efficacy after repeated dosing; when this occurs, it is not clear what principles should guide providing effective analgesia among opioid-dependent individuals. This within-subject inpatient study aimed to determine if physically dependent opioid abusers (n = 11) experience changes in oxycodone-induced analgesia during 2 oxycodone maintenance (30 mg orally 4 times per day) phases: initial stabilization (days 1-3) and after 6 weeks of chronic dosing. Six sessions (3 each phase), measured threshold, tolerance, and pain ratings for a Pressure Pain Test and Cold Pressor Test after a single double-blind dose of oxycodone 30 mg (initial stabilization) and 0, 30, and 60 mg (chronic dosing) given in place of a scheduled maintenance dose. Physiologic and opioid agonist effects were assessed during chronic dosing sessions. There was no analgesic response to oxycodone 30 mg. Oxycodone (60 mg) produced a 25% increase in peak Cold Pressor Test threshold compared with placebo, and significantly increased expired breath CO2, miosis, and ratings of abuse liability measures. These data suggest that more than twice the acute oxycodone maintenance dose is needed to produce robust acute analgesia, although adverse effects (eg, respiratory depression and abuse signals) may occur with lower doses. PERSPECTIVE: To understand sensitivity to opioid analgesia in opioid-dependent individuals, this article describes experimental pain, subjective and physiological responses during stabilization and after 6 weeks of oxycodone maintenance. Oxycodone produced euphoric effects and miosis with limited evidence of analgesia.
Copyright © 2017 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Opioid; analgesia; oxycodone; tolerance

Mesh:

Substances:

Year:  2017        PMID: 28274698      PMCID: PMC5484728          DOI: 10.1016/j.jpain.2017.02.433

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  28 in total

1.  Pressure algometry in manual therapy.

Authors:  L. Vanderweeën; R. A.B. Oostendorp; P. Vaes; W. Duquet
Journal:  Man Ther       Date:  1996-12

2.  Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.

Authors:  C F Samer; Y Daali; M Wagner; G Hopfgartner; C B Eap; M C Rebsamen; M F Rossier; D Hochstrasser; P Dayer; J A Desmeules
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  Opioid dose and drug-related mortality in patients with nonmalignant pain.

Authors:  Tara Gomes; Muhammad M Mamdani; Irfan A Dhalla; J Michael Paterson; David N Juurlink
Journal:  Arch Intern Med       Date:  2011-04-11

4.  Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans.

Authors:  Shanna Babalonis; Michelle R Lofwall; Paul A Nuzzo; Sharon L Walsh
Journal:  Addict Biol       Date:  2014-07-31       Impact factor: 4.280

5.  Can coadministration of oxycodone and morphine produce analgesic synergy in humans? An experimental cold pain study.

Authors:  Michael Grach; Wattan Massalha; Dorit Pud; Rivka Adler; Elon Eisenberg
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

Review 6.  Human pain responsivity in a tonic pain model: psychological determinants.

Authors:  Andrew C N Chen; Samuel F Dworkin; Joanna Haug; John Gehrig
Journal:  Pain       Date:  1989-05       Impact factor: 6.961

7.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

Review 8.  Experimental human pain models: a review of standardised methods for preclinical testing of analgesics.

Authors:  Camilla Staahl; Asbjørn Mohr Drewes
Journal:  Basic Clin Pharmacol Toxicol       Date:  2004-09       Impact factor: 4.080

9.  Validity of cross-friction algometry procedure in referred muscle pain syndromes: preliminary results of a new referred pain provocation technique with the aid of a Fischer pressure algometer in patients with nonspecific low back pain.

Authors:  Andre D Farasyn; Romain Meeusen; Jo Nijs
Journal:  Clin J Pain       Date:  2008-06       Impact factor: 3.442

10.  Lack of effect of chronic dextromethorphan on experimental pain tolerance in methadone-maintained patients.

Authors:  Peggy A Compton; Walter Ling; Matt A Torrington
Journal:  Addict Biol       Date:  2008-05-26       Impact factor: 4.280

View more
  3 in total

1.  Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals.

Authors:  Andrew S Huhn; Eric C Strain; George E Bigelow; Michael T Smith; Robert R Edwards; D Andrew Tompkins
Journal:  Anesthesiology       Date:  2019-01       Impact factor: 7.892

2.  Virtual Reality-Based Biofeedback and Guided Meditation in Rheumatology: A Pilot Study.

Authors:  R Swamy Venuturupalli; Timothy Chu; Marcus Vicari; Amit Kumar; Natalie Fortune; Ben Spielberg
Journal:  ACR Open Rheumatol       Date:  2019-11-11

3.  Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone.

Authors:  Gabrielle Agin-Liebes; Andrew S Huhn; Eric C Strain; George E Bigelow; Michael T Smith; Robert R Edwards; Valerie A Gruber; D Andrew Tompkins
Journal:  Drug Alcohol Depend       Date:  2021-06-25       Impact factor: 4.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.